Normalization of the tumor microenvironment: Evidence for tissue inhibitor of metalloproteinase-2 as a cancer therapeutic

Connective Tissue Research

Volumn 55, Issue 1, 2014, Pages 13-19

  Stetler Stevenson, William G ^a,b   Gavil, Noah Veis ^b,c  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c BOWDOIN COLLEGE   (United States)

Author keywords

Angiogenesis; Extracellular matrix; Homeostasis; Metalloproteinases; Progression

Indexed keywords

TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CHRONIC DISEASE; EXTRACELLULAR MATRIX; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; METASTASIS; NONHUMAN; PROTEIN DEGRADATION; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR MICROENVIRONMENT;

ANIMALS; EXTRACELLULAR MATRIX; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROTEOLYSIS; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TUMOR MICROENVIRONMENT;

EID: 84892694879     PISSN: 03008207     EISSN: 16078438     Source Type: Journal    
DOI: 10.3109/03008207.2013.867339     Document Type: Article

References (50)

1. Cox TR, Erler JT. Remodeling and homeostasis of the extracellular matrix: implications for fibrotic diseases and cancer. Dis Model Mech 2011;4:165-78.
2. Lu P, Weaver VM, Werb Z. The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol 2012;196:395-406.
3. Nelson CM, Bissell MJ. Modeling dynamic reciprocity: engineering three-dimensional culture models of breast architecture, function, and neoplastic transformation. Semin Cancer Biol 2005;15:342-52.
4. Hynes RO. The extracellular matrix: not just pretty fibrils. Science 2009;326:1216-19.
5. Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991;64:327-36.
6. Mueller MM, Fusenig NE. Friends or foes - bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 2004;4:839-49.
7. Rivera S, Khrestchatisky M, Kaczmarek L, Rosenberg GA, Jaworski DM. Metzincin proteases and their inhibitors: foes or friends in nervous system physiology? J Neurosci 2010;30: 15337-57.
8. Coussens LM. Matrix metalloproteinase inhibitors and cancer-trials and tribulations. Science 2002;295:2387-92.
9. Roy R, Yang J, Moses MA. Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J Clin Oncol 2009;27:5287-97.
10. Reisfeld RA. The tumor microenvironment: a target for combination therapy of breast cancer. Crit Rev Oncog 2013;18:115-33.
11. Brew K, Nagase H. The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity. BBA-Mol Cell Res Elsevier BV 2010;1803:55-71.
12. Nuttall RK, Sampieri CL, Pennington CJ, Gill SE, Schultz GA, Edwards DR. Expression analysis of the entire MMP and TIMP gene families during mouse tissue development. FEBS Lett 2004; 563:129-34.
13. Stetler-Stevenson WG. Tissue inhibitors of metalloproteinases in cell signaling: metalloproteinase-independent biological activities. Sci Signal 2008;1:re6. doi: 10.1126/scisignal.127re6.
14. Seo D-W, Li H, Guedez L, Wingfield PT, Diaz T, Salloum R, Wei B-Y, Stetler-Stevenson WG. TIMP-2 mediated inhibition of angiogenesis. Cell 2003;114:171-80.
15. Fernandez CA, Roy R, Lee S, Yang J, Panigrahy D, Van Vliet KJ, Moses MA. The anti-angiogenic peptide, loop 6, binds insulin-like growth factor-1 receptor. J Biol Chem 2010;285:41886-95.
16. Jung K-K, Liu X-W, Chirco R, Fridman R, Kim H-RC. Identification of CD63 as a tissue inhibitor of metalloproteinase-1 interacting cell surface protein. EMBO J. Nature Publishing Group 2006;25:3934-42.
17. Qi JH, Ebrahem Q, Moore N, Murphy G, Claesson-Welsh L, Bond M, Baker A, Anand-Apte B. A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nat Med 2003;9: 407-15.
18. Qi JH, Dai G, Luthert P, Chaurasia S, Hollyfield J, Weber BHF, Stöhr H, Anand-Apte B. S156C mutation in tissue inhibitor of metalloproteinases-3 induces increased angiogenesis. J Biol Chem ASBMB 2009;284:19927-36.
19. Pérez-Mart́nez L, Jaworski DM. Tissue inhibitor of metalloproteinase-2 promotes neuronal differentiation by acting as an antimitogenic signal. J Neurosci 2005;25:4917-29.
20. Moore CS, Milner R, Nishiyama A, Frausto RF, Serwanski DR, Pagarigan RR, Whitton JL, Miller RH, Crocker SJ. Astrocytic tissue inhibitor of metalloproteinase-1 (TIMP-1) promotes oligodendrocyte differentiation and enhances CNS myelination. J Neurosci 2011;31:6247-54.
21. Moore CS, Crocker SJ. An alternate perspective on the roles of TIMPs and MMPs in pathology. AJPA Elsevier Inc 2012;180: 12-16.
22. Suemitsu R, Yoshino I, Tomiyasu M, Fukuyama S, Okamoto T, Maehara Y. Serum tissue inhibitors of metalloproteinase-1 and-2 in patients with non-small cell lung cancer. Surg Today 2004;34: 896-901.
23. Nakada M, Kita D, Futami K, Yamashita J, Fujimoto N, Sato H, Okada Y. Roles of membrane type 1 matrix metalloproteinase and tissue inhibitor of metalloproteinases 2 in invasion and dissemination of human malignant glioma. J Neurosurg 2001;94:464-73.
24. Kachra Z, Beaulieu E, Delbecchi L, Mousseau N, Berthelet F, Moumdjian R, Del Maestro R, Béliveau R. Expression of matrix metalloproteinases and their inhibitors in human brain tumors. Clin Exp Metastasis 1999;17:555-66.
25. Lu H. The expression and clinical significance of matrix metalloproteinase 7 and tissue inhibitor of matrix metalloproteinases 2 in clear cell renal cell carcinoma. Exp Ther Med 2013;5:890-6.
26. Groblewska M, Mroczko B, Kozlowski M, Niklinski J, Laudanski J, Szmitkowski M. Serum matrix metalloproteinase 2 and tissue inhibitor of matrix metalloproteinases 2 in esophageal cancer patients. Folia Histochem Cytobiol 2012;50:590-8.
27. Honkavuori-Toivola M, Talvensaari-Mattila A, Soini Y, Turpeenniemi-Hujanen T, Santala M. Immunoreactivity for TIMP-2 is associated with a favorable prognosis in endometrial carcinoma. Tumour Biol 2012;33:935-41.
28. Walsh LA, Cepeda MA, Damjanovski S. Analysis of the MMPdependent and independent functions of tissue inhibitor of metalloproteinase-2 on the invasiveness of breast cancer cells. J Cell Commun Signal 2012;6:87-95.
29. Ha?oń A, Nowak-Markwitz E, Donizy P, Matkowski R, Maciejczyk A, Gansukh T, Györffy B, Spaczyński M, Zabel M, Lage H, Surowiak P. Enhanced immunoreactivity of TIMP-2 in the stromal compartment of tumor as a marker of favorable prognosis in ovarian cancer patients. J Histochem Cytochem 2012;60:491-501.
30. Hegab AE, Sakamoto T, Uchida Y, Nomura A, Ishii Y, Morishima Y, Mochizuki M, Kimura T, Saitoh W, Iizuka T, Kiwamoto T, Sekizawa K. Promoter activity of human tissue inhibitor of metalloproteinase 2 gene with novel single nucleotide polymorphisms. Respirology 2005;10:27-30.
31. De Clerck YA, Darville MI, Eeckhout Y, Rousseau GG. Characterization of the promoter of the gene encoding human tissue inhibitor of metalloproteinases-2 (TIMP-2). Gene 1994;139: 185-91.
32. Yang L, Gu H-J, Zhu H-J, Sun Q-M, Cong R-H, Zhou B, Tang N-P, Wang B. Tissue inhibitor of metalloproteinase-2 G-418 C polymorphism is associated with an increased risk of gastric cancer in a Chinese population. Eur J Surg Oncol 2008;34:636-41.
33. Srivastava P, Lone TA, Kapoor R, Mittal RD. Association of promoter polymorphisms in MMP2 and TIMP2 with prostate cancer susceptibility in North India. Arch Med Res 2012;43: 117-24.
34. Park KS, Kim SJ, Kim KH, Kim JC. Clinical characteristics of TIMP2, MMP2, and MMP9 gene polymorphisms in colorectal cancer. J Gastroenterol Hepatol 2011;26:391-7.
35. Alakus H, Afriani N, Warnecke-Eberz U, Bollschweiler E, Fetzner U, Drebber U, Metzger R, Hölscher AH, Mönig SP. Clinical impact of MMP and TIMP gene polymorphisms in gastric cancer. World J Surg 2010;34:2853-9.
36. Kang H-S, Kim S-K, Cho B-K, Kim Y-Y, Hwang Y-S, Wang K-C. Single nucleotide polymorphisms of tissue inhibitor of metalloproteinase genes in familial moyamoya disease. Neurosurgery 2006;58: 1074-80. discussion 1074-80.
37. Hsu C-H, Peng K-L, Kang M-L, Chen Y-R, Yang Y-C, Tsai C-H, Chu C-S, Jeng Y-M, Chen Y-T, Lin F-M, Huang H-D, Lu Y-Y, Teng Y-C, Lin S-T, Lin R-K, Tang F-M, Lee S-B, Hsu HM, Yu J-C, Hsiao P-W, Juan L-J. TET1 suppresses cancer invasion by activating the tissue inhibitors of metalloproteinases. Cell Rep 2012;2:568-79.
38. Hoegy SE, Oh HR, Corcoran ML, Stetler-Stevenson WG. Tissue inhibitor of metalloproteinases-2 (TIMP-2) suppresses TKR-growth factor signaling independent of metalloproteinase inhibition. J Biol Chem 2001;276:3203-14.
39. Seo D-W, Li H, Qu C-K, Oh J, Kim Y-S, Diaz T, Wei B, Han J-W, Stetler-Stevenson WG. Shp-1 mediates the antiproliferative activity of tissue inhibitor of metalloproteinase-2 in human microvascular endothelial cells. J Biol Chem 2006;281:3711-21.
40. Kim SH, Cho Y-R, Kim H-J, Oh JS, Ahn E-K, Ko H-J, Hwang BJ, Lee S-J, Cho Y, Kim YK, Stetler-Stevenson WG, Seo D-W. Antagonism of VEGF-A-induced increase in vascular permeability by an integrin a3b1-Shp-1-cAMP/PKA pathway. Blood 2012;120: 4892-902.
41. Lee S-J, Tsang PS, Diaz TM, Wei B-Y, Stetler-Stevenson WG. TIMP-2 modulates VEGFR-2 phosphorylation and enhances phosphodiesterase activity in endothelial cells. Lab Investig 2010; 90:374-82.
42. Bourboulia D, Jensen-Taubman S, Rittler MR, Han HY, Chatterjee T, Wei B, Stetler-Stevenson WG. Endogenous angiogenesis inhibitor blocks tumor growth via direct and indirect effects on tumor microenvironment. Am J Pathol 2011;179:2589-600.
43. Bourboulia D, Han H, Jensen-Taubman S, Gavil N, Isaac B, Wei B, Neckers L, Stetler-Stevenson WG. TIMP-2 modulates cancer cell transcriptional profile and enhances E-cadherin/beta-catenin complex expression in A549 lung cancer cells. Oncotarget 2013;4: 163-73.
44. Han H, Bourboulia D, Jensen-Taubman S, Isaac B, Wei B, Stetler-Stevenson WG. An endogenous inhibitor of angiogenesis inversely correlates with side population phenotype and function in human lung cancer cells. Oncogene 2013. [Epub ahead of print]. doi:10. 1038/onc.2013.61
45. Imren S, Kohn DB, Shimada H, Blavier L, DeClerck YA. Overexpression of tissue inhibitor of metalloproteinases-2 retroviral-mediated gene transfer in vivo inhibits tumor growth and invasion. Cancer Res 1996;56:2891-5.
46. De Clerck YA, Devasthali V, Perez N, Shimada H, Boone TC, Langley KE, Taylor SM. Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases. Cancer Res 1992;52:701-8.
47. Li H, Lindenmeyer F, Grenet C, Opolon P, Menashi S, Soria C, Yeh P, Perricaudet M, Lu H. AdTIMP-2 inhibits tumor growth, angiogenesis, and metastasis, and prolongs survival in mice. Hum Gene Ther 2001;12:515-26.
48. Kang WKW, Park E-KE, Lee HSH, Park B-YB, Chang J-YJ, Kim M-YM, Kang HAH, Kim J-YJ. A biologically active angiogenesis inhibitor, human serum albumin-TIMP-2 fusion protein, secreted from Saccharomyces cerevisiae. Protein Expr Purif 2007;53:331-8.
49. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med Nature Publishing Group 2001;7:987-9.
50. Goel S, Duda DG, Xu L, Munn LL, Boucher Y, Fukumura D, Jain RK. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev 2011;91:1071-121.